|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
US5994514A
(en)
|
1991-08-14 |
1999-11-30 |
Genentech, Inc. |
Immunoglobulin variants
|
|
CA2118508A1
(en)
|
1992-04-24 |
1993-11-11 |
Elizabeth S. Ward |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
WO1994029351A2
(en)
|
1993-06-16 |
1994-12-22 |
Celltech Limited |
Antibodies
|
|
US5595756A
(en)
*
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
|
JPH07291996A
(ja)
|
1994-03-01 |
1995-11-07 |
Yuu Honshiyo |
ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
PL220113B1
(pl)
|
1999-01-15 |
2015-08-31 |
Genentech Inc |
Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
|
|
AU7072700A
(en)
|
1999-08-23 |
2001-03-19 |
Dana-Farber Cancer Institute, Inc. |
Pd-1, a receptor for b7-4, and uses therefor
|
|
CA2383424C
(en)
|
1999-08-23 |
2011-02-15 |
Gordon Freeman |
Novel b7-4 molecules and uses therefor
|
|
AU2001260153B2
(en)
|
2000-03-24 |
2006-08-17 |
Micromet Ag |
Multifunctional polypeptides comprising a binding site to an epitope of the NKG2D receptor complex
|
|
EP1272526A4
(en)
|
2000-04-13 |
2004-10-13 |
Univ Rockefeller |
REINFORCING ANTIBODY-IMMUNE RESPONSE
|
|
ATE540579T1
(de)
|
2000-11-15 |
2012-01-15 |
Ono Pharmaceutical Co |
Pd-1-defiziente maus und ihre verwendung
|
|
ES2727425T3
(es)
|
2000-12-12 |
2019-10-16 |
Medimmune Llc |
Moléculas con semividas prolongadas, composiciones y usos de las mismas
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
ES2338534T3
(es)
|
2001-02-27 |
2010-05-10 |
The Governement Of The Usa, Represented By The Secretary Department Of Health And Human Services |
Analogos de talidomina como inhibidores de la angiogenesis.
|
|
BR0207854A
(pt)
|
2001-03-07 |
2004-08-24 |
Merck Patent Gmbh |
Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
|
|
AR036993A1
(es)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US7662925B2
(en)
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
DE10161767T1
(de)
|
2002-07-03 |
2018-06-07 |
Honjo Tasuku |
Immunopotenzierende Zusammensetzungen, die einen Anti-PD-L1 Antikörper enthalten
|
|
WO2004042017A2
(en)
|
2002-10-31 |
2004-05-21 |
Genentech, Inc. |
Methods and compositions for increasing antibody production
|
|
EP1576014B1
(en)
|
2002-12-23 |
2011-06-29 |
Wyeth LLC |
Antibodies against pd-1 and uses thereof
|
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
US7355008B2
(en)
|
2003-01-09 |
2008-04-08 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
ES2729974T3
(es)
|
2003-01-23 |
2019-11-07 |
Ono Pharmaceutical Co |
Anticuerpo específico de PD-1 y CD3 humanas
|
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
|
AU2004266159A1
(en)
|
2003-08-22 |
2005-03-03 |
Biogen Idec Ma Inc. |
Improved antibodies having altered effector function and methods for making the same
|
|
US20060134105A1
(en)
|
2004-10-21 |
2006-06-22 |
Xencor, Inc. |
IgG immunoglobulin variants with optimized effector function
|
|
EP1697520A2
(en)
|
2003-12-22 |
2006-09-06 |
Xencor, Inc. |
Fc polypeptides with novel fc ligand binding sites
|
|
GB0400440D0
(en)
|
2004-01-09 |
2004-02-11 |
Isis Innovation |
Receptor modulators
|
|
EP1810979B1
(en)
|
2004-09-22 |
2012-06-20 |
Kyowa Hakko Kirin Co., Ltd. |
STABILIZED HUMAN IgG4 ANTIBODIES
|
|
TW200639163A
(en)
|
2005-02-04 |
2006-11-16 |
Genentech Inc |
RAF inhibitor compounds and methods
|
|
CN1296385C
(zh)
*
|
2005-03-30 |
2007-01-24 |
王哲 |
抗猪生长激素单克隆抗体及制备方法及应用
|
|
EP2161336B2
(en)
|
2005-05-09 |
2017-03-29 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
|
AU2006265108C1
(en)
|
2005-07-01 |
2013-01-17 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
|
|
KR101434935B1
(ko)
|
2005-11-30 |
2014-10-01 |
애브비 인코포레이티드 |
아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의용도
|
|
EP1957460A1
(en)
|
2005-12-08 |
2008-08-20 |
Millennium Pharmaceuticals, Inc. |
Bicyclic compounds with kinase inhibitory activity
|
|
EP2004688B2
(en)
|
2006-03-23 |
2014-03-05 |
BioArtic Neuroscience AB |
Improved protofibril selective antibodies and the use thereof
|
|
JP5271895B2
(ja)
|
2006-05-15 |
2013-08-21 |
メルク・シャープ・アンド・ドーム・コーポレーション |
抗糖尿病性の二環式化合物
|
|
CN101104640A
(zh)
|
2006-07-10 |
2008-01-16 |
苏州大学 |
抗人pd-l1单克隆抗体制备及应用
|
|
CA2662905A1
(en)
|
2006-07-10 |
2008-01-17 |
Biogen Idec Ma Inc. |
Compositions and methods for inhibiting growth of smad4-deficient cancers
|
|
US20080227704A1
(en)
*
|
2006-12-21 |
2008-09-18 |
Kamens Joanne S |
CXCL13 binding proteins
|
|
NZ600281A
(en)
|
2006-12-27 |
2013-03-28 |
Harvard College |
Compositions and methods for the treatment of infections and tumors
|
|
WO2008145142A1
(en)
|
2007-05-31 |
2008-12-04 |
Genmab A/S |
Stable igg4 antibodies
|
|
US7615883B2
(en)
|
2007-06-06 |
2009-11-10 |
Meheen H Joe |
Wind driven venturi turbine
|
|
AU2014201367B2
(en)
|
2007-06-18 |
2016-01-28 |
Merck Sharp & Dohme B.V. |
Antibodies to human programmed death receptor pd-1
|
|
AU2008266951C1
(en)
|
2007-06-18 |
2025-06-19 |
Merck Sharp & Dohme B.V. |
Antibodies to human programmed death receptor PD-1
|
|
US9243052B2
(en)
|
2007-08-17 |
2016-01-26 |
Daniel Olive |
Method for treating and diagnosing hematologic malignancies
|
|
RU2010119450A
(ru)
|
2007-10-16 |
2011-11-27 |
ЭсБиАй БАЙОТЕК КО.,ЛТД. (JP) |
Антитело против bst2
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
EP2262837A4
(en)
*
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
WO2010027827A2
(en)
|
2008-08-25 |
2010-03-11 |
Amplimmune, Inc. |
Targeted costimulatory polypeptides and methods of use to treat cancer
|
|
JP5794917B2
(ja)
|
2008-09-12 |
2015-10-14 |
アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ |
Ｐｄ−１特異抗体およびその使用
|
|
US8927697B2
(en)
|
2008-09-12 |
2015-01-06 |
Isis Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
ES2592216T3
(es)
|
2008-09-26 |
2016-11-28 |
Dana-Farber Cancer Institute, Inc. |
Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos
|
|
KR101050829B1
(ko)
|
2008-10-02 |
2011-07-20 |
서울대학교산학협력단 |
항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
|
|
SI2370593T1
(sl)
|
2008-11-28 |
2016-08-31 |
Emory University |
Postopek za določanje učinkovitosti antagonista pd-1
|
|
KR20190069615A
(ko)
|
2008-12-09 |
2019-06-19 |
제넨테크, 인크. |
항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
|
|
US20100197924A1
(en)
|
2008-12-22 |
2010-08-05 |
Millennium Pharmaceuticals, Inc. |
Preparation of aminotetralin compounds
|
|
US8741295B2
(en)
|
2009-02-09 |
2014-06-03 |
Universite De La Mediterranee |
PD-1 antibodies and PD-L1 antibodies and uses thereof
|
|
LT2406284T
(lt)
|
2009-03-10 |
2016-10-10 |
Biogen Ma Inc. |
Antikūnai prieš b ląstelių subrendimo antigenus
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
JP5774595B2
(ja)
|
2009-10-28 |
2015-09-09 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｇｌｐ−１ｒ抗体及びそれらの使用
|
|
US10053513B2
(en)
|
2009-11-30 |
2018-08-21 |
Janssen Biotech, Inc. |
Antibody Fc mutants with ablated effector functions
|
|
HUE030100T2
(en)
|
2010-02-19 |
2017-04-28 |
Xencor Inc |
New CTLA4-IG immunoadhesins
|
|
EP2545078A1
(en)
|
2010-03-11 |
2013-01-16 |
UCB Pharma, S.A. |
Pd-1 antibody
|
|
US9296815B2
(en)
|
2010-03-29 |
2016-03-29 |
Zymeworks Inc. |
Antibodies with enhanced or suppressed effector function
|
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
|
RS57895B2
(sr)
|
2011-03-29 |
2025-02-28 |
Roche Glycart Ag |
Fc varijante antitela
|
|
DK2691112T3
(en)
|
2011-03-31 |
2018-07-30 |
Merck Sharp & Dohme |
STABLE FORMULATIONS OF ANTIBODIES AGAINST HUMAN PD (PROGRAMMED DEATH) 1- RECEPTOR AND RELATED TREATMENTS
|
|
RS57324B1
(sr)
|
2011-04-20 |
2018-08-31 |
Medimmune Llc |
Antitela i drugi molekuli koji vezuju b7-h1 i pd-1
|
|
BR112013028420A2
(pt)
|
2011-05-02 |
2017-01-24 |
Ym Biosciences Australia Pty |
tratamento de mieloma múltiplo
|
|
PT3424953T
(pt)
|
2011-06-06 |
2020-11-03 |
Novo Nordisk As |
Anticorpos terapêuticos
|
|
TR201820873T4
(tr)
|
2011-08-01 |
2019-01-21 |
Hoffmann La Roche |
Pd-1 ekseni bağlayıcı antagonistler ve mek inhibitörlerinin kullanıldığı kanser tedavisine yönelik yöntemler.
|
|
WO2013079174A1
(en)
|
2011-11-28 |
2013-06-06 |
Merck Patent Gmbh |
Anti-pd-l1 antibodies and uses thereof
|
|
WO2013118858A1
(ja)
|
2012-02-09 |
2013-08-15 |
中外製薬株式会社 |
抗体のFc領域改変体
|
|
US10011660B2
(en)
|
2012-04-30 |
2018-07-03 |
Medimmune, Llc |
Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
|
|
KR20240135058A
(ko)
|
2012-05-15 |
2024-09-10 |
브리스톨-마이어스 스큅 컴퍼니 |
Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법
|
|
KR102410078B1
(ko)
|
2012-05-31 |
2022-06-22 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
Pd-l1에 결합하는 항원 결합 단백질
|
|
AU2013267267B2
(en)
|
2012-05-31 |
2017-10-26 |
Genentech, Inc. |
Methods of treating cancer using PD-L1 axis binding antagonists and VEGF antagonists
|
|
HK1208810A1
(en)
|
2012-07-03 |
2016-03-18 |
Janssen Alzheimer Immunotherapy |
C-terminal and central epitope a-beta antibodies
|
|
EP2890715B1
(en)
|
2012-08-03 |
2020-12-16 |
Dana-Farber Cancer Institute, Inc. |
Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use
|
|
JP6461800B2
(ja)
|
2012-10-04 |
2019-01-30 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
ヒトモノクローナル抗ｐｄ−ｌ１抗体および使用方法
|
|
CA2889182A1
(en)
|
2012-10-26 |
2014-05-01 |
The University Of Chicago |
Synergistic combination of immunologic inhibitors for the treatment of cancer
|
|
WO2014100490A1
(en)
|
2012-12-19 |
2014-06-26 |
Adimab, Llc |
Multivalent antibody analogs, and methods of their preparation and use
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
TWI635098B
(zh)
|
2013-02-01 |
2018-09-11 |
再生元醫藥公司 |
含嵌合恆定區之抗體
|
|
SI2840892T1
(en)
|
2013-02-20 |
2018-08-31 |
Regeneron Pharmaceuticals, Inc. |
Animals other than humans with modified immunoglobulin heavy chain sequences
|
|
AU2014240101B2
(en)
|
2013-03-15 |
2018-05-17 |
Regeneron Pharmaceuticals, Inc. |
IL-33 antagonists and uses thereof
|
|
CA3175360C
(en)
|
2013-05-31 |
2024-05-28 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind pd-1
|
|
CN108715615B
(zh)
|
2013-09-13 |
2020-11-27 |
百济神州(广州)生物科技有限公司 |
抗pd1抗体及其作为治疗剂与诊断剂的用途
|
|
CN110156892B
(zh)
|
2014-07-03 |
2023-05-16 |
百济神州有限公司 |
抗pd-l1抗体及其作为治疗剂及诊断剂的用途
|
|
BR112017001385B1
(pt)
|
2014-07-22 |
2023-12-05 |
Cb Therapeutics, Inc. |
Anticorpo isolado ou fragmento do mesmo que liga a pd-1, uso deste, composição, polinucleotídeo isolado e vetor de expressão
|
|
CA2956399A1
(en)
|
2014-08-05 |
2016-02-11 |
Cb Therapeutics, Inc. |
Anti-pd-l1 antibodies
|
|
US9139653B1
(en)
|
2015-04-30 |
2015-09-22 |
Kymab Limited |
Anti-human OX40L antibodies and methods of treatment
|
|
MA42447A
(fr)
|
2015-07-13 |
2018-05-23 |
Cytomx Therapeutics Inc |
Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation
|
|
WO2017024465A1
(en)
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|